Cindy Martinez
General Practice · Hormigueros, PRNPI 1700947009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Amgen at 47.9% of the total.
Across 3 payments — averaging $85.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$124
- Kyowa Kirin, Inc.$115
- IBSA Pharma Inc.$19
Across 1,106 payments — averaging $2902.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.2M
- Avanir Pharmaceuticals, Inc.$855K
- Eisai Inc.$588K
- Esperion Therapeutics, Inc.$371K
- Sanofi US Services Inc.$114K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$57K
- plus $68K from 2 others
What the payments were for
- Food & beverage$258100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $124 |
| Kyowa Kirin, Inc. | 1 | $115 |
| IBSA Pharma Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$258 in reported general payments places this provider in the 60th percentile of 3,586 general practice providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 21 | $6,689 |
| Rosuvastatin Calcium | 32 | $760 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 15 | $586 |
| Atorvastatin Calcium | 51 | $459 |
| Diclofenac Sodium | 12 | $388 |
| Ketoconazole | 12 | $313 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $274 |
| Clarithromycin | 12 | $263 |
| Losartan Potassium | 24 | $245 |
| Omeprazole | 15 | $239 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $203 |
| Levothyroxine Sodium | 40 | $138 |
| Gabapentin | 23 | $115 |
| Amlodipine Besylate | 19 | $112 |
| Pantoprazole Sodium | 19 | $110 |
Paid to pharmacies, not to this prescriber.
Other general practice in Hormigueros
- Simon CarloHormigueros$5K
- Wilfredo CuevasSan Lorenzo$530K
- Julio BacoMayaguez$268K
- Soria Diaz BaezPonce$192K
- Carlos RomanCanovanas$140K
- William E TorresSan Juan$86K
- Rafael Mendoza RodriguezPonce$77K
- Frank Perez NogueiraSan German$70K
- Vivian Tamayo AgraitSan Juan$64K
- William Soto AvilesToa Baja$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.